2 patient evaluations for Cyclosporine ophthalmic with a burden rating of Not at all hard to take

30 members have decided to share their profiles only with other members of PatientsLikeMe.

Feb 12, 2016 (Started Oct 11, 2009)

  • Effectiveness
    Major (for dry eyes)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 0.2 g Daily
Advice & Tips: the benefits continue.
Cost: < $25 monthly

Sep 19, 2015 (Started Oct 11, 2009)

  • Effectiveness
    Major (for dry eyes)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 0.2 g Daily
Advice & Tips: This remains extremely effective.
Cost: < $25 monthly

May 27, 2012 (Started Oct 11, 2009)

  • Effectiveness
    Major (for dry eyes)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 0.2 g Daily
Advice & Tips: Restasis was originally prescribed for my very dry eyes. Now I know the dry eye condition caused my tearing and Conjunctivitis. I'm so glad that my eyes no longer tear all day and I can now open my eyes upon awakening and I can see clearly. Before this medication when I woke, I had to unglue my eye lashes, rinse out my eyes and wait about an hour (for the tearing to subside), before I could even attempt to read anything.
Cost: $200+ monthly

Jan 21, 2010 (Started Oct 11, 2009)

  • Effectiveness
    Major (for dry eyes)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 0.2 g Daily
Advice & Tips: It takes about a month of usage before you actually notice a real difference in how much tearing, blurry vision you still have. I'm happy to again be able to easily read. :-)
Cost: $200+ monthly

  • 0 helpful marks

May 1, 2014 (Started Dec 31, 2012)

  • Effectiveness
    Slight (for dry eye syndrome)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 4 drop(s) Daily
Cost: < $25 monthly

  • 0 helpful marks
Last updated:
Showing 2 of 2 patient evaluations for Cyclosporine ophthalmic